Inactive Instrument

Audentes Therapeutics, Inc. Share Price

US05070R1041

Biotechnology & Medical Research

Latest news: Audentes Therapeutics, Inc.

14/03/24	Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	CI
07/11/22	Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	CI
20/10/22	Taysha Gene Therapies, Inc. announced that it expects to receive $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	CI
24/12/20	Audentes Therapeutics, Inc. Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy	CI
21/08/20	Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy	CI
21/04/20	Audentes Therapeutics, Inc. Appoints Julie Person as Senior Vice President, Human Resources	CI
18/02/20	Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina	CI
15/01/20	Audentes Therapeutics, Inc. Announces Management Changes	CI
15/01/20	Audentes Therapeutics, Inc. Approves a Change in the Company’s Fiscal Year to End on March 31	CI
15/01/20	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P TMI Index	CI
15/01/20	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Biotechnology Select Industry Index	CI
15/01/20	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Global BMI Index	CI
14/01/20	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Composite Index	CI

More news

Press Releases: Audentes Therapeutics, Inc.

15/01/20	AUDENTES THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
16/12/19	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	BU
16/12/19	AUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
03/12/19	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	PR
03/12/19	AUDENTES THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

News in other languages: Audentes Therapeutics, Inc.

03/12/19	NASDAQ COMPOSITE : Wall Street poursuit son repli, un accord USA-Chine s'éloigne
03/12/19	DOW JONES 30 : Wall Street ouvre dans le rouge, un accord USA-Chine s'éloigne
03/12/19	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
03/12/19	USA-Les valeurs à suivre à Wall Street (actualisé)
03/12/19	Astellas Pharma : Pharmakonzern Astellas kauft für 3 Mrd Dollar US-Gentherapiespezialisten

More news

Managers and Directors: Audentes Therapeutics, Inc.

Manager	Title	Age	Since
Morten Sogaard PSD	President	-	-
Jason Schwartz CTO	Chief Tech/Sci/R&D Officer	-	31/05/2022
David Smethurst LAW	General Counsel	-	31/07/2021

Director	Title	Age	Since
Alan Beggs BRD	Director/Board Member	-	-
Kush Parmar BRD	Director/Board Member	45	30/06/2013

More insiders

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/01/20	Louis Lange	Tender	Director	368,575	0.8037%
15/01/20	Jennifer Jarrett	Issuer sale	Director	53,200	0.1160%
15/01/20	Thomas Soloway	Tender	Chief Financial Officer	407,257	0.8881%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AUDENTES THERAPEUTICS, INC.	-.--%	-0.03%	-	-	2.77B
WUXI APPTEC CO., LTD.	-4.10%	-8.35%	+38.48%	+66.99%	66.22B
ARGENX SE	-0.41%	+3.27%	+10.46%	+73.74%	55.2B
LONZA GROUP AG	+1.06%	+4.34%	+12.50%	+92.31%	52.79B
IQVIA HOLDINGS INC.	+0.48%	+2.92%	+28.04%	+51.85%	45.53B
BEONE MEDICINES AG	-1.39%	+2.01%	+21.70%	+126.15%	43.94B
REVOLUTION MEDICINES, INC.	-3.37%	-0.63%	+254.96%	+924.57%	41.64B
CELLTRION, INC.	-1.67%	+8.06%	+14.17%	+56.67%	34B
WUXI BIOLOGICS (CAYMAN) INC.	-8.38%	-9.01%	+25.65%	-1.82%	25.84B
GENMAB A/S	+1.30%	+4.94%	+38.23%	+28.03%	23.51B
Average	-1.66%	+3.43%	+49.36%	+157.61%	43.19B
Weighted average by Cap.	-1.70%	+3.43%	+48.05%	+160.35%

Audentes Therapeutics, Inc. Share Price

Stocks

US05070R1041

Biotechnology & Medical Research

Latest news: Audentes Therapeutics, Inc.

Press Releases: Audentes Therapeutics, Inc.

News in other languages: Audentes Therapeutics, Inc.

Managers and Directors: Audentes Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile